Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?

Lexaria Bioscience Corp LEXX has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD).

• The data showed that after a single day of dosing, the processed CBD reduced arterial stiffness, potentially broadening its application to the treatment of cardiovascular and other disease states beyond hypertension.
• Related Link: Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension.
• Arterial stiffness can also be a prognostic marker for cardiovascular events and all-cause mortality, even in asymptomatic individuals without overt cardiovascular disease.
• Arterial stiffness was measured through pulse wave velocity (PWV) evaluation, together with assessments of augmentation index and pressure. 
• All comparisons between DehydraTECH-CBD and placebo were statistically significant (p < 0.01).
• Related Link: Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures.
• Price Action: LEXX shares are up 14.20% at $5.62 during the premarket session on the last check Wednesday.